SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets EIR for Vadodara API manufacturing facility from USFDA

10 Jun 2025 Evaluate

Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its API manufacturing facility located at Dabhasa near Vadodara. This facility underwent an inspection from April 21 to April 25 2025 and has been classified as Voluntary Action Indicated (VAI). FDA confirmed the inspection as closed.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

946.35 7.15 (0.76%)
17-Apr-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1682.60
Dr. Reddys Lab 1223.00
Cipla 1237.70
Zydus Lifesciences 946.35
Lupin 2317.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×